U.S. Markets closed

GlaxoSmithKline's Redfern on Drug Pricing

Jan.11 -- GlaxoSmithKline Chief Strategy Officer David Redfern discusses drug pricing and mergers and acquisition activity under a Trump administration. He speaks on "What’d You Miss?"